Disparities in Linkage to Care Among Children With Hepatitis C Virus in the United States.

Saved in:
Bibliographic Details
Title: Disparities in Linkage to Care Among Children With Hepatitis C Virus in the United States.
Authors: Curtis, Megan Rose, Munroe, Sarah, Biondi, Breanne E., Ciaranello, Andrea L., Linas, Benjamin P., Epstein, Rachel L.
Source: Pediatrics. May2025, Vol. 155 Issue 5, p1-8. 1p.
Subjects: Health services accessibility, African Americans, Research funding, Logistic regression analysis, Hispanic Americans, Retrospective studies, Antiviral agents, Pediatrics, Race, Odds ratio, Medical records, Acquisition of data, Hepatitis C, Health equity, Comparative studies, Confidence intervals, Adolescence, Children
Geographic Terms: United States
Abstract: BACKGROUND AND OBJECTIVES: Pediatric HCV cases have increased in the United States. Guidelines recommend beginning treatment of HCV for children as young as 3 years old. However, no studies have evaluated pediatric linkage to HCV care and direct-acting antiviral (DAA) uptake on a national level. This study aims to characterize the HCV care cascade among a national cohort of children with HCV. METHODS: This retrospective cohort analysis included children born between 2000 and 2018 who were diagnosed with HCV between the ages of 0 and 18 years. We analyzed TriNetX Research Network data, a US national electronic health records network. Primary HCV care cascade outcomes included the number of children diagnosed with HCV infection, linked to care, and prescribed DAAs. We assessed the association between race and ethnicity with linkage to care using logistic regression. RESULTS: Among 928 children with HCV, 297 (32.0%) linked to HCV care and 111 (12.0%) were prescribed a DAA. Hispanic/Latinx children had double and white children had triple the odds of linkage compared with Black children (odds ratio [OR], 2.20; 95% CI, 1.05–4.59; OR, 3.44; 95% CI, 1.89–6.28) after adjusting for sex, birth cohort, and region. CONCLUSIONS: Pediatric access to HCV care remains low. Fewer than 1 in 3 children linked to HCV care and fewer than 1 in 8 were treated. This study uncovers racial and ethnic disparities in HCV care access. Targeting interventions toward increasing linkage to care could represent an opportunity to advance HCV elimination goals and reduce disparities. [ABSTRACT FROM AUTHOR]
Copyright of Pediatrics is the property of American Academy of Pediatrics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:BACKGROUND AND OBJECTIVES: Pediatric HCV cases have increased in the United States. Guidelines recommend beginning treatment of HCV for children as young as 3 years old. However, no studies have evaluated pediatric linkage to HCV care and direct-acting antiviral (DAA) uptake on a national level. This study aims to characterize the HCV care cascade among a national cohort of children with HCV. METHODS: This retrospective cohort analysis included children born between 2000 and 2018 who were diagnosed with HCV between the ages of 0 and 18 years. We analyzed TriNetX Research Network data, a US national electronic health records network. Primary HCV care cascade outcomes included the number of children diagnosed with HCV infection, linked to care, and prescribed DAAs. We assessed the association between race and ethnicity with linkage to care using logistic regression. RESULTS: Among 928 children with HCV, 297 (32.0%) linked to HCV care and 111 (12.0%) were prescribed a DAA. Hispanic/Latinx children had double and white children had triple the odds of linkage compared with Black children (odds ratio [OR], 2.20; 95% CI, 1.05–4.59; OR, 3.44; 95% CI, 1.89–6.28) after adjusting for sex, birth cohort, and region. CONCLUSIONS: Pediatric access to HCV care remains low. Fewer than 1 in 3 children linked to HCV care and fewer than 1 in 8 were treated. This study uncovers racial and ethnic disparities in HCV care access. Targeting interventions toward increasing linkage to care could represent an opportunity to advance HCV elimination goals and reduce disparities. [ABSTRACT FROM AUTHOR]
ISSN:00314005
DOI:10.1542/peds.2024-068565